An anti-aging drug may help protect the brain before Alzheimer's symptoms begin — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- University of Missouri researchers gave healthy adults ages 45-65 a low daily dose of rapamycin for four weeks and then measured their brain blood flow.
- APOE4 carriers showed improved brain blood flow after treatment, whereas participants without the genetic variant did not show the same benefit.
- Women carrying APOE4 experienced the largest improvements in brain blood flow; women account for nearly two-thirds of people living with Alzheimer’s disease.
- Ai-Ling Lin previously found that rapamycin slowed brain aging and increased blood flow in APOE4 mice, prompting the investigation in humans.
- Rapamycin is already used to prevent immune rejection of transplanted organs and treat certain rare conditions, while its anti-aging applications remain under study.
- The EXPRESS pilot trial, published in the Journal of Cerebral Blood Flow & Metabolism in 2026, did not establish whether rapamycin prevents Alzheimer’s disease or preserves memory; it measured short-term circulation changes.
Why it matters: The trial gives researchers a sharper population for subsequent studies: healthy APOE4 carriers ages 45-65 showed brain-blood-flow gains after four weeks of low-dose rapamycin, noncarriers did not, and women carriers benefited most. Because memory preservation and lower Alzheimer’s incidence were not established, the result remains a biomarker finding rather than prevention evidence.
Ask SkimNews
